Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

June 24, 2014

Primary Completion Date

April 13, 2017

Study Completion Date

April 21, 2017

Conditions
NauseaVomitingGlioma
Interventions
DRUG

aprepitant

On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).

DRUG

ondansetron

On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke, Durham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Katy Peters

OTHER

NCT01450826 - Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | Biotech Hunter | Biotech Hunter